Myotonic disorders
Clinical trials for Myotonic disorders explained in plain language.
Never miss a new study
Get alerted when new Myotonic disorders trials appear
Sign up with your email to follow new studies for Myotonic disorders, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug AOC 1001 tested for Long-Term safety in rare muscle disease
Disease control CompletedThis study is a follow-up to an earlier trial, testing the long-term safety and effects of a drug called AOC 1001 in adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. 37 participants who completed the first study received multiple doses of AOC 1001 by IV infu…
Matched conditions: MYOTONIC DISORDERS
Phase 2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a Muscle-Relaxing drug offer Long-Term relief for children with myotonia?
Disease control CompletedThis trial evaluates the long-term safety and effectiveness of mexiletine in children aged 6 to 18 with myotonic disorders, conditions where muscles have trouble relaxing after contraction. Participants, who previously completed a study of mexiletine, receive the drug for about 8…
Matched conditions: MYOTONIC DISORDERS
Sponsor: Lupin Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Hope for muscle strength: new drug targets myotonic dystrophy
Disease control CompletedThis phase 3 trial tests an experimental drug called AOC 1001 in 159 adults with myotonic dystrophy type 1, a genetic condition that causes muscle weakness and stiffness. Participants receive either the drug or a placebo by intravenous infusion. The main goal is to see if the dru…
Matched conditions: MYOTONIC DISORDERS
Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug AOC 1001 tested for rare muscle disease
Disease control CompletedThis study tested a new drug called AOC 1001 in 39 adults with myotonic dystrophy type 1, a genetic muscle disorder. Participants received either the drug or a placebo by IV infusion. The goal was to check safety and how the drug moves through the body. Results will help decide i…
Matched conditions: MYOTONIC DISORDERS
Phase 1/2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC